Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (Q34504188)

18

object named as

William G Wierda

1 reference

2 August 2017

Matthew S Davids

2

1 reference

2 August 2017

John M Pagel

3

1 reference

2 August 2017

Brad S Kahl

4

1 reference

2 August 2017

Soham D Puvvada

5

1 reference

2 August 2017

John F Gerecitano

6

1 reference

2 August 2017

Thomas J Kipps

7

1 reference

2 August 2017

Mary Ann Anderson

8

1 reference

2 August 2017

Jennifer R Brown

9

1 reference

2 August 2017

Lori Gressick

10

1 reference

2 August 2017

Shekman Wong

11

1 reference

2 August 2017

Martin Dunbar

12

1 reference

2 August 2017

Ming Zhu

13

1 reference

2 August 2017

Monali B Desai

14

1 reference

2 August 2017

Elisa Cerri

15

1 reference

2 August 2017

Sari Heitner Enschede

16

1 reference

2 August 2017

Rod A Humerickhouse

17

1 reference

2 August 2017

John F Seymour

The New England Journal of Medicine

19

1 reference

2 August 2017

language of work or name

English

0 references

publication date

6 December 2015

1 reference

2 August 2017

1 reference

2 August 2017

374

1 reference

2 August 2017

311-322

1 reference

2 August 2017

4

1 reference

2 August 2017

Dose escalation methods in phase I cancer clinical trials

1 reference

12 December 2020

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Risk categories and refractory CLL in the era of chemoimmunotherapy

1 reference

12 December 2020

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

The tumor lysis syndrome

1 reference

12 December 2020

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

12 December 2020

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

1 reference

12 December 2020

miR-15 and miR-16 induce apoptosis by targeting BCL2

1 reference

12 December 2020

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

12 December 2020

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

12 December 2020

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience

1 reference

12 December 2020

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

12 December 2020

Apoptosis therapy: driving cancers down the road to ruin

1 reference

12 December 2020

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

12 December 2020

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

1 reference

12 December 2020

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

12 December 2020

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

12 December 2020

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

12 December 2020

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

12 December 2020

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

1 reference

12 December 2020

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

1 reference

12 December 2020

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Programmed anuclear cell death delimits platelet life span.

1 reference

12 December 2020

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

1 reference

12 December 2020

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

12 December 2020

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

12 December 2020

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

12 December 2020

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

1 reference

12 December 2020